|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immature platelet fraction as a predictor of platelet recovery following hematopoietic progenitor cell transplantation显示文摘 | Zucker ML Murphy CA Rachel JM | 2006 | Lab Hematol2006，12，3： | 1 |
| 2 | Immature platelet fraction as a predictor of platelet recovery following hematopoietic progenitor cell transplantation 显示文摘 | Zueker ML Murphy CA Rachel JM | 2006 | Lab Hematol2006，12，3： | 1 |
| 3 | A solid-phase red cell adherence test for platelet cross-matching 显示文摘 | Rachel JM Sinor LT Tawfik OW | 1985 | Med Lab Sci1985，42，2： | 1 |
| 4 | Mechanism of thrombocytopenia in hepatitis cas determined by the immature platelet fraction 显示文摘 | Zucker ML Skikne BS Rachel JM et al | 2007 | Abstracts2007，110，： | 1 |
| 5 | A solid phase antiixMy screen 显示文摘 | Plapp FV Sinor LT Rachel JM | 1984 | AmJ Clin Pathol1984，82，6： | 1 |
| 6 | Acute fractures of the scaphoid显示文摘 | Haisman JM Rachel SR Andrew JW | 2006 | J Bone Joint Surg Am2006，88，4： | 1 |
| 7 | Immature platelet frac-tionas a predictor of platelet recovery following hematopoietic pro-genitor cell transplantation显示文摘 | Zucker ML Murphy CA Rachel JM | 2006 | Lab Hematol2006，12，3： | 1 |
| 8 | Left ventricular hy- pertrophy in the renal patient显示文摘 | Rachel JM Patrick SP Robert NF | 2001 | J Am Soc Nephrol2001，12，： | 1 |
| 9 | Immature platelet fraction as a predictor of platelet recovery following hematopoietic progenitor cell transplantation 显示文摘 | Zucker ML Murphy CA Rachel JM | 2006 | Lab Hematol2006，12，3： | 1 |
| 10 | Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies显示文摘The use of immune checkpoint inhibitors(iCls)has increased exponentially in the past decade,although its progress specifically for breast cancer has been modest.The first U.S.Food and Drug Administration approval for ICl in breast cancer came in 2019,eight years after the first-ever approval of an ICl.At present,current indications for ICls are relevant only to a subset of patients with triple-negative breast cancer,or those displaying high microsatellite instability or deficiency in the mismatch repair protein pathway.With an increasing understanding of the limitations of using ICls,which stem from breast cancer being innately poorly immunogenic,as well as the presence of various intrinsic and acquired resistance pathways,ongoing trials are evaluating different combination therapies to overcome these barriers.In this review,we aim to describe the development timeline of ICls and resistance mechanisms limiting their utility,and summarise the available approaches and ongoing trials relevant to overcoming each resistance mechanism. | Rachel SJ Wong Rebecca JM Ong Joline SJ Lim | 2023 | Cancer Drug Resistance2023，6，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员